Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai Yarkoni with a vision of enabling regenerative medicine to become reality. Realizing that stem cells are one of the pillars of the 21st century medicine, first development was around enabling the mass enrichment of stem cells as a raw material for any and all regenerative treatments. Without such technologies, stem cells based treatments will remain within the confines of laboratories and clinical trials. For regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes. Cellect was driven by its wish to become the main provider of technologies for pharma companies and medical centers that will make the production of stem cells based products a trivial, safe and inexpensive process. Source
No articles found.
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Avinger is a commercial-stage medical device company that designs, manufactures an...
Avinger is a commercial-stage medical device co...
As a leading provider of innovative technologies for the treatment of Atrial Fibri...
As a leading provider of innovative technologie...
DermTech is the global leader in molecular dermatology, bringing precision medicin...
DermTech is the global leader in molecular derm...
HJLI specializes in developing and manufacturing bioprosthetic medical devices to ...
HJLI specializes in developing and manufacturin...
ILLUSIO is a plastic surgery simulation tool that enables a surgeon and patient to...
ILLUSIO is a plastic surgery simulation tool th...
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
MiMedxŽ is a biopharmaceutical company developing, manufacturing and marketing reg...
MiMedxŽ is a biopharmaceutical company developi...
Join the National Investor Network and get the latest information with your interests in mind.